CYNTHIA JOANNE MEININGER
Pilots at Wind Rdg Cv, Georgetown, TX
License number
Texas A4472193
Issued Date
Jun 2016
Expiration Date
Jun 2018
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
213 Wind Ridge Cv, Georgetown, TX 78628
Professional information
Endothelium-Targeting Nanoparticle For Reversing Endothelial Dysfunction
US Patent:
2007008, Apr 19, 2007
Filed:
Oct 10, 2006
Appl. No.:
11/545370
Inventors:
Cynthia Meininger - Georgetown TX, US
International Classification:
A61K 48/00
US Classification:
424093200, 514044000
Abstract:
The present invention includes delivery of isolated and purified nucleic acids that encode GTPCH proteins in nanoparticles for the treatment of endothelial cells damaged by diabetes, smoking, dyslipidemia, hypertension, and cardiovascular disease. The nanoparticles contain a nucleic acid sequence, polymer and a targeting ligand. The targeting ligand facilitates the selective delivery of the nucleic acid sequence to damaged endothelial cells. Examples involving a nucleic acid sequence encoding GTP-cyclohydrolase I (GTPCH), PEG/PEI polymers, and a monoclonal antibody or other molecule that binds to the lectin-like oxidized low density lipoprotein (LDL) receptor-1 (Lox-1) or associated molecules are presented.
Endothelium-Targeting Nanoparticle For Reversing Endothelial Dysfunction
US Patent:
2005005, Mar 10, 2005
Filed:
Sep 3, 2004
Appl. No.:
10/934226
Inventors:
Cynthia Meininger - Georgetown TX, US
Assignee:
The Texas A&M University System - College Station TX
International Classification:
A61K048/00, A61K039/395, C12N015/85
US Classification:
424093210, 424178100, 435455000
Abstract:
The present invention includes delivery of isolated and purified nucleic acids that encode GTPCH proteins in nanoparticles for the treatment of endothelial cells damaged by diabetes, smoking, dyslipidemia, hypertension, and cardiovascular disease. The nanoparticles contain a nucleic acid sequence, polymer and a targeting ligand. The targeting ligand facilitates the selective delivery of the nucleic acid sequence to damaged endothelial cells. Examples involving a nucleic acid sequence encoding GTP-cyclohydrolase I (GTPCH), PEG/PEI polymers, and a monoclonal antibody or other molecule that binds to the lectin-like oxidized low density lipoprotein (LDL) receptor-1 (Lox-1) or associated molecules are presented.